Oncolytics Biotech: response to anal cancer therapy lasts about 15 months
Oncolytics Biotech reports a median response of about 15 months in GOBLET Cohort 4 and plans studies that could support registration in anal cancer.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Oncolytics Biotech reported that the median duration of response in GOBLET Cohort 4 was approximately 15 months. According to TradingView, which relied on a filing submitted to the SEC, every patient who responded survived beyond one year. For comparison, the approved retifanlimab monotherapy has historically reported 9.5 months. Median overall survival has not yet been reached, and several patients have lived beyond 24 months.
Following Fast Track Designation from the FDA and discussions with regulators, the company plans to explore studies that could support potential registration in anal cancer. It may also look at pelareorep combined with a checkpoint inhibitor in HPV-associated head and neck cancer.
why it matters
For markets, this is mainly news about a small biotech issuer. Early-stage data and registration plans usually move the shares of a narrow group of companies, while the broader market reacts only weakly. Future trial results and regulatory decisions will be the key items to watch.
tags
instruments
sources
- Oncolytics Biotech Reports ~15-Month Response Duration in Anal Cancer Study — TradingView, 27 October 2026 at 13:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗